Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment.
Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén and Amanda Sandström (Capital Markets and Public M&A) as well as Arvid Weimers (Banking and Finance).
